Filing Details

Accession Number:
0001209191-15-025201
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-11 16:40:08
Reporting Period:
2015-03-10
Filing Date:
2015-03-11
Accepted Time:
2015-03-11 16:40:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1367920 Concert Pharmaceuticals Inc. CNCE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1594782 Pauline Mcgowan C/O Concert Pharmaceuticals, Inc.
99 Hayden Avenue, Suite 500
Lexington MA 02421
Vp, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-10 8,849 $1.13 8,849 No 4 M Direct
Common Stock Disposition 2015-03-10 8,849 $13.90 0 No 4 S Direct
Common Stock Acquisiton 2015-03-10 6,194 $1.13 6,194 No 4 M Direct
Common Stock Disposition 2015-03-10 6,194 $13.90 0 No 4 S Direct
Common Stock Acquisiton 2015-03-10 7,079 $3.79 7,079 No 4 M Direct
Common Stock Disposition 2015-03-10 7,079 $13.90 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2015-03-10 8,849 $0.00 8,849 $1.13
Common Stock Employee Stock Option (right to buy) Disposition 2015-03-10 6,194 $0.00 6,194 $1.13
Common Stock Employee Stock Option (right to buy) Disposition 2015-03-10 7,079 $0.00 7,079 $3.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-06-04 No 4 M Direct
0 2017-12-11 No 4 M Direct
0 2020-12-03 No 4 M Direct
Footnotes
  1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $13.68 to $14.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. Immediately.